New Cochrane review on anti-amyloid Alzheimer’s drugs (opens in new tab)

Over the past few years we’ve heard evidence from clinical trials of the amyloid beta-targeting monoclonal antibodies, like aducanumab, lecanemab and donanemab for Alzheimer’s disease. Bodies like the MHRA, NICE and the EMA have looked at the data and made decisions about whether to approve or recommend these drugs. There have been different views within the scientific community about the extent to which these drugs work, cause side-effects, and offer a clinically meaningful benefit.